Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198

Cancer Research

Volumn 75, Issue 22, 2015, Pages 4790-4802

  Molenaar, Remco J ^a   Botman, Dennis ^a   Smits, Myrthe A ^a   Hira, Vashendriya V ^a   Van Lith, Sanne A ^b   Stap, Jan ^a   Henneman, Peter ^a   Khurshed, Mohammed ^a   Lenting, Krissie ^b   Mul, Adri N ^a   Dimitrakopoulou, Dionysia ^a   Van Drunen, Cornelis M ^a   Hoebe, Ron A ^a   Radivoyevitch, Tomas ^c   Wilmink, Johanna W ^a   Maciejewski, Jaroslaw P ^c   Vandertop, W Peter ^a,d   Leenders, William P ^b   Bleeker, Fonnet E ^a   Van Noorden, Cornelis J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; AGI 5198; ANTINEOPLASTIC AGENT; DOUBLE STRANDED DNA; ISOCITRATE DEHYDROGENASE 1; METFORMIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; AGI-5198; BENZENEACETAMIDE DERIVATIVE; ENZYME INHIBITOR; IDH1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; ISOCITRATE DEHYDROGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; GENE; GENE MUTATION; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; IDH1 GENE; OVERALL SURVIVAL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RADIATION PROTECTION; RADIOSENSITIVITY; ADVERSE EFFECTS; BIOSYNTHESIS; CHEMORADIOTHERAPY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; GENETICS; GLIOBLASTOMA; IN VITRO STUDY; MUTATION; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZENEACETAMIDES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DNA METHYLATION; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCK-IN TECHNIQUES; GLIOBLASTOMA; HUMANS; IMIDAZOLES; IN VITRO TECHNIQUES; ISOCITRATE DEHYDROGENASE; MUTATION; NADP; OXIDATIVE STRESS; RADIATION TOLERANCE;

EID: 84955054496     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3603     Document Type: Article

References (59)

1. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta 2014;1846:326-41.
2. van Lith SA, Navis AC, Verrijp K, Niclou SP, Bjerkvig R, Wesseling P, et al. Glutamate as chemotactic fuel for diffuse glioma cells: are they glutamate suckers? Biochim Biophys Acta 2014;1846:66-74.
3. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
4. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261-5.
5. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, et al. The prognostic IDH1(R132)mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010;119:487-94.
6. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44.
7. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011;12:463-9.
8. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30.
9. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-83.
10. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
11. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014;16:1263-73.
12. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013;32:3091-100.
13. Labussiere M, Sanson M, Idbaih A, Delattre JY. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 2010;15: 196-9.
14. Abdel-Wahab O, Levine RL. Metabolism and the leukemic stem cell. J Exp Med 2010;207:677-80.
15. Shi J, Sun B, Shi W, Zuo H, Cui D, Ni L, et al. DecreasingGSHand increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumour Biol 2015;36:655-62.
16. Mohrenz IV, Antonietti P, Pusch S, Capper D, Balss J, Voigt S, et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 2013;18:1416-25.
17. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol 2013;15:57-68.
18. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32:783-90.
19. Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 2014;16:414-20.
20. Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol 2012;108:11-27.
21. Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011;43:1256-61.
22. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature 2014;513:110-4.
23. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626-30.
24. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622-6.
25. Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA, et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 2014;289:13717-25.
26. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122:2877-87.
27. Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem 2015;290:762-74
28. Fernandez SL, Russell DW, Hurlin PJ. Development of human gene reporter cell lines using rAAV mediated homologous recombination. Biol Proced Online 2007;9:84-90.
29. Esmaeili M, Hamans BC, Navis AC, van Horssen R, Bathen TF, Gribbestad IS, et al. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res 2014;74:4898-907.
30. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118:599-601.
31. Chieco P, Jonker A, De Boer BA, Ruijter JM, Van Noorden CJ. Image cytometry: protocols for 2D and 3D quantification inmicroscopic images. Prog Histochem Cytochem 2013;47:211-333.
32. Shi Q, Karuppagounder SS, Xu H, Pechman D, Chen H, Gibson GE. Responses of the mitochondrial alpha-ketoglutarate dehydrogenase complex to thiamine deficiency may contribute to regional selective vulnerability. Neurochem Int 2007;50:921-31.
33. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
34. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
35. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 2014;30:1363-9.
36. Aten JA, Stap J, Krawczyk PM, van Oven CH, Hoebe RA, Essers J, et al. Dynamics of DNA double-strand breaks revealed by clustering of damaged chromosome domains. Science 2004;303:92-5.
37. Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 2014;127:221-33.
38. Latini A, Scussiato K, Rosa RB, Llesuy S, Bello-Klein A, Dutra-Filho CS, et al. D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur J Neurosci 2003;17:2017-22.
39. Kolker S, Pawlak V, Ahlemeyer B, Okun JG, Horster F, Mayatepek E, et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci 2002;16:21-8.
40. Reitman ZJ, Sinenko SA, Spana EP, Yan H. Genetic dissection of leukemiaassociated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila. Blood 2015;125:336-45.
41. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012;483:484-8.
42. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, et al. IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. Cancer Res 2014; 74:3317-31.
43. Cuyas E, Fernandez-Arroyo S, Corominas-Faja B, Rodriguez-Gallego E, Bosch-Barrera J, Martin-Castillo B, et al. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 2015; 6:12279-96.
44. Wolf DA. Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? Cancer Cell 2014;26:788-95.
45. Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Hirsh C, et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 2015 Apr 3. [Epub ahead of print].
46. Peters AL, Van Noorden CJ. Glucose-6-phosphate dehydrogenase deficiency andmalaria: cytochemical detection of heterozygous G6PD deficiency in women. J Histochem Cytochem 2009;57:1003-11.
47. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
48. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225-34.
49. Yang B, Zhong C, Peng Y, Lai Z, Ding J. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H. Cell Res 2010;20:1188-200.
50. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015;21:178-84.
51. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 2012;35:571-87.
52. Sasaki M, Knobbe CB, Itsumi M, Elia AJ, Harris IS, Chio II, et al. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 2012;26:2038-49.
53. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-7.
54. Molenaar RJ, van Noorden CJ. Type 2 diabetes and cancer as redox diseases? Lancet 2014;384:853.
55. van Lith SA, Molenaar R, van Noorden CJ, Leenders WP. Tumor cells in search for glutamate: an alternative explanation for increased invasiveness of IDH1 mutant gliomas. Neuro Oncol 2014;16:1669-70.
56. Chen R, Nishimura MC, Kharbanda S, Peale F, Deng Y, Daemen A, et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma. Proc Natl Acad Sci U S A 2014;111:14217-22.
57. Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem 2014;289:23318-28.
58. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010;70:8981-7.
59. Elhammali A, Ippolito JE, Collins L, Crowley J, Marasa J, Piwnica-Worms D. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov 2014;4: 828-39.